X

Trial Profile

A study assessing ALV-304 in Inflammatory Bowel Disease

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 15 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALV 304 (Primary)
Indications Inflammatory bowel diseases
Focus Adverse reactions

Most Recent Events

15 Apr 2021 According to a PureTech Health media release, the company is planning to file an IND for ALV-304 in Inflammatory Bowel Disease (IBD) in 2023.
05 Oct 2020 According to a PureTech Health media release, the company announced a $3.3 million US Department of Defense (DoD) Technology/Therapeutic Development Award which will support preclinical research and development activities to potentially enable the filing of an investigational new drug (IND) application for ALV-304.
04 Sep 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com